Disc Medicine initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Disc Medicine with an Overweight rating and $45 price target. The safety of bitopertin has already been established, and evidence so far supports its ability to modulate heme synthesis, which would be effective in treating erythropoietic protoporphyria and possibly other indications, the analyst tells investors in a research note. The firm expects positive signals from the data readouts from the bitopertin program in 2023.